<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5160CE88-742A-40D0-8C3B-711665EA2583"><gtr:id>5160CE88-742A-40D0-8C3B-711665EA2583</gtr:id><gtr:firstName>Ken</gtr:firstName><gtr:surname>Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E829ECFE-6EDA-42B8-9342-C3C98DC8EB3D"><gtr:id>E829ECFE-6EDA-42B8-9342-C3C98DC8EB3D</gtr:id><gtr:firstName>Afzal</gtr:firstName><gtr:surname>Chaudhry</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/227456ED-709C-4E97-8A1A-F8322CFCC5F7"><gtr:id>227456ED-709C-4E97-8A1A-F8322CFCC5F7</gtr:id><gtr:firstName>Alvis</gtr:firstName><gtr:surname>Brazma</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/491A5874-115C-4E1F-A4C6-D73C4166F590"><gtr:id>491A5874-115C-4E1F-A4C6-D73C4166F590</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Jayne</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CD781082-FBE7-4078-A38C-30FB33021494"><gtr:id>CD781082-FBE7-4078-A38C-30FB33021494</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Lyons</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400929"><gtr:id>B72CBA23-5A96-467A-AEAB-51EC0AA49B69</gtr:id><gtr:title>Expression Profiling and the Clinical Course of Systemic Vasculitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400929</gtr:grantReference><gtr:abstractText>Systemic vasculitis (AASV), caused when the immune system attacks the body, is a severe disease with a high risk of renal failure and premature death. As it is hard to predict how the disease will progress or respond to toxic immune suppressive therapy, such treatment may be used excessively, risking side effects such as infection and cancer. Clinicians, bioinformaticians, and immunologists have teamed up in Cambridge to study patients with vasculitis using modern technology to detect patterns of gene expression in blood cells. These patterns will be integrated with clinical information, providing new ways to measure disease activity and predict response to treatment. New tests thus generated may enable targeting of therapy to people who most need it, improving treatment effectiveness and reducing toxicity.</gtr:abstractText><gtr:technicalSummary>Autoimmune diseases are major public health problems that affect 8-10% of the adult population. They have variable clinical features and often demonstrate unpredictable responses to therapy. ANCA-associated systemic vasculitis (AASV) is one such autoimmune disease, characterised by vascular inflammation and often severe tissue damage, with an incidence of 40/million/year. The optimal choice and length of treatment regimens is not known and no good markers predict therapeutic response or disease flare. There is therefore an urgent need to develop methods to predict the need for, and duration of, treatment in patients with AASV. Such ?biomarkers? might also provide an early definition of remission allowing truncation of treatment, or herald relapse allowing pre-emptive, briefer or less toxic therapy.

The Cambridge / Hinxton Centre for Translational Research in Autoimmune Disease (CHiC TRIAD) is a group of clinicians, bioinformaticians, and immunologists formed with the aim of integrating both clinical and microarray data in a cross-sectional and prospective fashion using state-of-the-art bioinformatics. Similar approaches have proven to be successful in the field of oncology, where microarray-based diagnostics are already entering clinical practice. We will study AASV before, during and after therapy with both conventional treatment and novel biological therapies. Microarray assays using purified leucocyte subsets will produce expression data which will be integrated with clinical, serological and immunological data using existing and novel informatics tools. This unique resource will allow us to define patterns of gene expression that will predict responses to treatment and that will also uncover novel ways of determining disease activity and of predicting drug toxicity. Tests generated from these findings will improve patient outcome by leading to better targeted therapy, with significant and beneficial effects on drug-related toxicity and treatment efficacy. In the longer term these techniques should be useful in the management of other autoimmune diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2008-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>295707</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>565333</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Project Grant</gtr:description><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>5982E33F-4F14-470A-8D87-CBD38253CBD9</gtr:id><gtr:outcomeId>252999B32A90</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>86981</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Evelyn Trust, Project Grant</gtr:description><gtr:fundingOrg>The Evelyn Trust</gtr:fundingOrg><gtr:id>A62A757E-C195-4827-9829-A9753ED9FD99</gtr:id><gtr:outcomeId>9E7F159B3AA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81981</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NACC Project Grant</gtr:description><gtr:fundingOrg>National Association for Colitis and Crohn?s Disease (NACC)</gtr:fundingOrg><gtr:id>684A7C45-E41A-4E82-97E0-E4F90B2DF6DE</gtr:id><gtr:outcomeId>F32982A46210</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1052088</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Programme Grant</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/L019027/1</gtr:fundingRef><gtr:id>ECA00131-480D-4824-B07E-568795F9EAAA</gtr:id><gtr:outcomeId>54579138c7e888.28362856</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49650</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Project Grant</gtr:description><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>725FD6A7-48E2-4EB9-9948-F4502D2C553D</gtr:id><gtr:outcomeId>1D955096FBD0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Fellowship</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>522BA15A-8219-4BED-8487-681277A70DBC</gtr:id><gtr:outcomeId>465AE9D2D8B0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Senior Investigator Award</gtr:department><gtr:description>Wellcome Trust Investigator Award</gtr:description><gtr:end>2021-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>200871/Z/16/Z</gtr:fundingRef><gtr:id>492CEB82-BEC5-40F9-88C2-52BA2C2F7F2D</gtr:id><gtr:outcomeId>58be81ea3e9346.04628803</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>516647</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Translation Award</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>099450/Z/12/Z</gtr:fundingRef><gtr:id>BE13961F-F0B2-4795-B554-60B7E91897EC</gtr:id><gtr:outcomeId>WRfwwKgGc1d</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>242463</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Fellowship</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D34F9683-8BD0-4452-AEF7-E199C25F1702</gtr:id><gtr:outcomeId>88D41901BEC0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Distiguished Innovator Pilot Grant</gtr:description><gtr:end>2015-11-02</gtr:end><gtr:fundingOrg>Lupus Research Institute</gtr:fundingOrg><gtr:id>BAA91BD3-88A9-47C6-BE02-8D79CC81E029</gtr:id><gtr:outcomeId>e9iFkGFLGAi</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>eQTL analysis of multiple cell types in health and disease.</gtr:description><gtr:id>681B7170-E573-44D5-8343-7B671FDD946A</gtr:id><gtr:impact>This technique led to two publications.</gtr:impact><gtr:outcomeId>58be82ca170fd5.55541216</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>eQTL Analysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The analysis of gene expression of leucocyte subsets enabled the identification of gene signatures of both pathogenic relevance and with better disease discrimination than those identified in PBMCs</gtr:description><gtr:id>F82A683D-5B00-41FD-B032-33C2258E544D</gtr:id><gtr:impact>This approach provides substantial advantages in the search for diagnostic and prognostic biomarkers in autoimmune disease.</gtr:impact><gtr:outcomeId>5B124824036</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>gene expression analysis of purified leucocyte subsets</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DB033E09-A00D-4A6A-A2BC-0C161996FFCF</gtr:id><gtr:title>Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification.</gtr:title><gtr:parentPublicationTitle>BMC genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/269a2fd1d07590e52dbcfd99716c568a"><gtr:id>269a2fd1d07590e52dbcfd99716c568a</gtr:id><gtr:otherNames>Lyons PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1471-2164</gtr:issn><gtr:outcomeId>845A2ED827E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10EC323A-CA72-4E96-8C45-4B929AC13EAB</gtr:id><gtr:title>Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>BMC medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fec1e28e82cdcbe7da0b21664bd8b392"><gtr:id>fec1e28e82cdcbe7da0b21664bd8b392</gtr:id><gtr:otherNames>Carr EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2350</gtr:issn><gtr:outcomeId>30858F51E76</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EA265AB-6150-420E-B263-CE988B89F816</gtr:id><gtr:title>T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f084a8afe838871a23ed77117eb117d"><gtr:id>5f084a8afe838871a23ed77117eb117d</gtr:id><gtr:otherNames>McKinney EF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>56dea81a8c7f40.83444190</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9DAEA220-789D-4923-B816-8D7CC3F6A7C5</gtr:id><gtr:title>Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fde02352204dc97dbc4b2d2bcabbcae"><gtr:id>2fde02352204dc97dbc4b2d2bcabbcae</gtr:id><gtr:otherNames>Pepper RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>pm_15949_29_23423260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70907F0E-2EF6-4E26-B84E-568ED06E3023</gtr:id><gtr:title>Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50e6243a98509e54910c6932cb74b8db"><gtr:id>50e6243a98509e54910c6932cb74b8db</gtr:id><gtr:otherNames>Lee JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>pm_15949_29_21946256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCBF3A04-6BB5-41F1-9282-4892ED902521</gtr:id><gtr:title>High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e609c93e50cf84eb6f996eef53a4a485"><gtr:id>e609c93e50cf84eb6f996eef53a4a485</gtr:id><gtr:otherNames>Kain R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>pm_15949_29_22323643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E97EC0BE-CA75-40E2-A4D6-D1BF04F0FF66</gtr:id><gtr:title>The Contribution of Transcriptomics to Biomarker Development in Systemic Vasculitis and SLE.</gtr:title><gtr:parentPublicationTitle>Current pharmaceutical design</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecf0e2b46060ca9ed954b2b1dc9af38d"><gtr:id>ecf0e2b46060ca9ed954b2b1dc9af38d</gtr:id><gtr:otherNames>Flint SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1381-6128</gtr:issn><gtr:outcomeId>5675e0d841520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CB9282E-ABDD-4E40-9AB6-FF704CA9B921</gtr:id><gtr:title>Comparison of gene expression microarray data with count-based RNA measurements informs microarray interpretation.</gtr:title><gtr:parentPublicationTitle>BMC genomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8613ec951ce3324a5d34f8a6c1bb5839"><gtr:id>8613ec951ce3324a5d34f8a6c1bb5839</gtr:id><gtr:otherNames>Richard AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2164</gtr:issn><gtr:outcomeId>doi_55f9839838f5dc93</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF4F6FA8-8536-4E2E-A73D-C2D07C9E5719</gtr:id><gtr:title>Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options.</gtr:title><gtr:parentPublicationTitle>Journal of molecular medicine (Berlin, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a53c3817013593c16ba17f54a0261a61"><gtr:id>a53c3817013593c16ba17f54a0261a61</gtr:id><gtr:otherNames>Strau? R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0946-2716</gtr:issn><gtr:outcomeId>5a2fd6ee796f74.97159069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD2836CB-6FB8-47FF-A3CD-FD28A594B87C</gtr:id><gtr:title>Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>Current opinion in rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ecf0e2b46060ca9ed954b2b1dc9af38d"><gtr:id>ecf0e2b46060ca9ed954b2b1dc9af38d</gtr:id><gtr:otherNames>Flint SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1040-8711</gtr:issn><gtr:outcomeId>5675df1a1d5d8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC6F388E-6094-4BC0-9C2E-27D7E26AD82A</gtr:id><gtr:title>Genetically distinct subsets within ANCA-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/269a2fd1d07590e52dbcfd99716c568a"><gtr:id>269a2fd1d07590e52dbcfd99716c568a</gtr:id><gtr:otherNames>Lyons PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15949_29_22808956</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>400C9AB4-D670-4F8C-B5E5-97B0AB5DB970</gtr:id><gtr:title>A CD8+ T cell transcription signature predicts prognosis in autoimmune disease.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f084a8afe838871a23ed77117eb117d"><gtr:id>5f084a8afe838871a23ed77117eb117d</gtr:id><gtr:otherNames>McKinney EF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>jBPb8xSf9tm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DBD1436-2ACE-45DD-9FCB-BBBE153F9202</gtr:id><gtr:title>Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis.</gtr:title><gtr:parentPublicationTitle>Annals of the rheumatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/269a2fd1d07590e52dbcfd99716c568a"><gtr:id>269a2fd1d07590e52dbcfd99716c568a</gtr:id><gtr:otherNames>Lyons PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-4967</gtr:issn><gtr:outcomeId>ABCEF008ECC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCF98CB9-B47A-4D8F-9A9E-0ED5825A90FF</gtr:id><gtr:title>Insight into Genotype-Phenotype Associations through eQTL Mapping in Multiple Cell Types in Health and Immune-Mediated Disease.</gtr:title><gtr:parentPublicationTitle>PLoS genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8a2cef77720c0f63f6ac585e3a1170c2"><gtr:id>8a2cef77720c0f63f6ac585e3a1170c2</gtr:id><gtr:otherNames>Peters JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7390</gtr:issn><gtr:outcomeId>56dea7c5e0b0c6.59189499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45AB385D-1DFB-40D9-A4A2-A8AE54E095BD</gtr:id><gtr:title>Genome-wide methylation analyses of primary human leukocyte subsets identifies functionally important cell-type-specific hypomethylated regions.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c9301a9512cd12667b2a6636c84eb4a"><gtr:id>3c9301a9512cd12667b2a6636c84eb4a</gtr:id><gtr:otherNames>Zilbauer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_15949_29_24159175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FF34327-22DC-47A8-9755-8C8ABE42D7A5</gtr:id><gtr:title>Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis.</gtr:title><gtr:parentPublicationTitle>BMC medical genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fec1e28e82cdcbe7da0b21664bd8b392"><gtr:id>fec1e28e82cdcbe7da0b21664bd8b392</gtr:id><gtr:otherNames>Carr EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-2350</gtr:issn><gtr:outcomeId>FBEF80A9EFF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41BABC2F-C86D-4060-B31F-3084C77AC788</gtr:id><gtr:title>Targeted genomic analysis reveals widespread autoimmune disease association with regulatory variants in the TNF superfamily cytokine signalling network.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8613ec951ce3324a5d34f8a6c1bb5839"><gtr:id>8613ec951ce3324a5d34f8a6c1bb5839</gtr:id><gtr:otherNames>Richard AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>585d3d13475857.49390115</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD12B7C8-C918-45D9-939B-4442FC1D59DA</gtr:id><gtr:title>Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50e6243a98509e54910c6932cb74b8db"><gtr:id>50e6243a98509e54910c6932cb74b8db</gtr:id><gtr:otherNames>Lee JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>pm_15949_29_24035192</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400929</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>